@article {Kragh:2003:1019-6439:305,
title = "In vivo chamber angiogenesis assay: An optimized Matrigel plug assay for fast assessment of anti-angiogenic activity",
journal = "International Journal of Oncology",
parent_itemid = "infobike://sp/ijo",
publishercode ="sp",
year = "2003",
volume = "22",
number = "2",
publication date ="2003-02-01T00:00:00",
pages = "305-311",
itemtype = "ARTICLE",
issn = "1019-6439",
eissn = "1791-2423",
url = "https://www.ingentaconnect.com/content/sp/ijo/2003/00000022/00000002/art00009",
author = "Kragh and Hjarnaa and Bramm and Kristjansen and Rygaard and Binderup",
abstract = "Efficient in vitro and in vivo angiogenesis assays, to assess and compare anti-angiogenic activity are a prerequisite for the discovery and characterization of anti-angiogenic targets. Here we describe an optimized Matrigel plug assay based on subcutaneously implanted chambers and two
fast and reproducible measuring techniques. Plexiglas ring/nylon net filter-chambers (0.2 ml) containing growth factor-reduced Matrigel and 300 ng basic fibroblast growth factor (bFGF) were subcutaneously implanted into the right flank of rats. Chamber angiogenesis was scored on day 5 and
day 10 post-implantation by computer image analysis of the chamber, and by optical density reading at 415 nm of a PBS solution of the chamber content. bFGF significantly induced chamber angiogenesis and histological examination confirmed that numerous blood vessels were present in the bFGF-induced
chambers. The anti-angiogenic control compound TNP-470 (10 mg/kg/d s.c.) completely inhibited the bFGF-induced angiogenesis. In contrast, the anti-inflammatory or immuno-suppressive compounds cyclosporin A (15 mg/kg/d p.o.), indomethacin (1 mg/kg/d p.o.), and prednisolone (5 mg/kg/d p.o.)
showed no anti-angiogenic activity, indicating that the bFGF-induced angiogenesis was not driven by an inflammatory response or by a foreign body reaction. Finally, two candidate anti-angiogenic compounds were tested in the assay. Continuous low-dose therapy with cyclophosphamide (25 mg/kg/d
p.o.) significantly inhibited bFGF-induced angiogenesis, whereas 1,25-dihydroxyvitamin D3 (0.5 \textmug/kg/d p.o.) showed no significant anti-angiogenic activity. In conclusion, this in vivo chamber angiogenesis assay is a useful new tool for drug evaluation as well as research into
anti-angiogenesis.",
}